^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastric Cancer
    Drug:Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    BMC Cancer
    Title:

    Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

    Published date:
    12/15/2023
    Excerpt:
    Compared with RC48 monotherapy, ICIs plus RC48 demonstrated superior third-line and beyond therapeutic efficacy for HER2-positive or HER2-low advanced and metastatic gastric cancer patients with manageable safety.
    Secondary therapy:
    Immune Checkpoint Inhibitors
    DOI:
    10.1186/s12885-023-11735-z.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gastric Cancer
    Title:

    Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.

    Published date:
    05/04/2021
    Excerpt:
    Fifty-seven patients were enrolled...RC48 also showed promising efficacy, with ORR of 15.0% (3/20) and DCR of 45.0% (9/20)....RC48 was well tolerated and showed promising antitumor activity in HER2-positive solid tumors, including gastric cancer...
    DOI:
    https://doi.org/10.1007/s10120-021-01168-7
    Trial ID:
    NCT02881190